Ultragenyx generates gross margins between 77.9% and 89.8%, but operating margin stayed negative in every reported quarter, reaching -124.3% in 2026Q1, which suggests R&D intensity has not yet translated into operating leverage.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | -$1.16-5.5% vs -$1.10 | $173M-5.2% vs $182M |
Q3 2026 Aug 4, 2026 | -$0.90+26.2% vs -$1.22 | $214M+16.9% vs $183M |
Q2 2026 May 5, 2026 | -$1.84-23.7% vs -$1.49 | $136M-14.0% vs $158M |
Q1 2026 Feb 12, 2026 | -$1.29-7.5% vs -$1.20 | $207M+4.2% vs $199M |
Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains highly concentrated in CRYSVITA, with new launches contributing minimally. Pipeline setbacks and terminated programs have forced a pivot from high-risk optionality to a leaner rare-disease commercial model.
Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Howard Horn - Executive VP of Corporate Strategy & CFO Erik Harris - Executive VP & Chief Commercial Officer Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Joon Lee Jaena Han - TD Cowen, Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.
Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027.
Ultragenyx (RARE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $1.81 per share a year ago.
Benchmark RARE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Ultragenyx Pharmaceutical Inc. (RARE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | -607.51% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $300.88 | $8.87B | 41.21 | 33.94% | 47.91% | 17.02% | — |
Ultragenyx Pharmaceutical Inc. (RARE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Ultragenyx Pharmaceutical Inc. (RARE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Oct 19, 2026·SEC
Oct 14, 2026·SEC
Get notified when RARE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ultragenyx Pharmaceutical Inc. (RARE) stock FAQ — growth, dividends, profitability & financials explained
Ultragenyx Pharmaceutical Inc. (RARE) reported $730.0M in revenue over the trailing twelve months. Revenue was $673.0M in fiscal year 2025.
Ultragenyx Pharmaceutical Inc. (RARE) grew revenue by 15.8% over the trailing twelve months, compared with the twelve months before.
No. Ultragenyx Pharmaceutical Inc. (RARE) reported a net loss of $524.0M over the trailing twelve months.
Ultragenyx Pharmaceutical Inc. (RARE) had a return on equity (ROE) of -607.5% in fiscal year 2025. A negative ROE means the company lost money over the period.
Ultragenyx Pharmaceutical Inc. (RARE) had negative free cash flow of $441.8M over the trailing twelve months.
